One third of hypovascular hypointense nodules in HBP become hypervascular 'progressed' HCC, with a 1-and 3-year cumulative incidence of 25 and 41%, respectively. Therefore, these hypovascular nodules should be strictly followed up or definitely treated as typical HCC. Due to this capability of identifying the precursors and biological behavior of HCC, EOB-MRI has rapidly become a key imaging tool for the diagnosis of HCC and its precursors, despite the scarce MRI availability throughout Europe. With increasing experience, EOB-MRI may eventually be established as the diagnostic imaging modality of choice in this setting. Full recognition by the Western EASL-AASLD guidelines is expected.
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common type of cancer and the third leading cause of cancerrelated death worldwide [1] . In the USA and Europe, HCC incidence is increasing rapidly, largely driven by the hepatitis C virus epidemic and nonalcoholic fatty liver disease, with a reported 41% increase in mortality from HCC over the last 2 decades [1] [2] [3] . The prognosis depends on tumor stage at diagnosis, being more favorable in early-stage HCC when curative options can be offered, which allow a 5-year overall survival rate approximating 40-70% [4] .
There are two different concepts of early HCC, based either on clinical staging or pathological characteristics. The most used clinical staging in the USA and Europe refers to the Barcelona Clinic Liver Cancer (BCLC) classification [5] , which was first endorsed by both the European Association for the Study of the Liver (EASL) [6] and the American Association for the Study of Liver Diseases (AASLD) guidelines for the management of HCC [7] , and confirmed in 2012 by the joint guidelines of the EASL and the European Organization for Research and Treatment of Cancer (EORTC) [8] [9] [10] . This staging system classifies the presence of a single tumor <2 cm in diameter without vascular invasion/satellites as very early HCC (BCLC stage 0), and patients with single tumors of 2-5 cm or a maximum of 3 nodules <3 cm in diameter as early HCC (BCLC stage A). Recent data have shown a 5-year survival of 80-90% with resection [11] and liver transplantation [12, 13] , and of 70% with local ablation [14] in BCLC stage 0 patients [8] and a median 5-year survival of 50-70% after resection, liver transplantation or local ablation in selected candidates [8] opposed to a natural outcome with median survival of around 3 years in BCLC stage A patients.
Pathological Staging
Pathological staging defines small HCC as HCC in the early stages of carcinogenesis (generally ≤ 2 cm), distinguishing two subclasses: the vaguely nodular type (size approx. 12 mm without local invasiveness) and the distinctly nodular type (mean size 16 mm) which might show local invasiveness. Vaguely nodular types are verywell-differentiated HCCs which contain bile ducts and portal veins, have an ill-defined nodular appearance and, by definition, have not yet invaded other structures [15] . The distinctly nodular type shows local metastases surrounding the nodule in 10% of cases and microscopic portal invasion in up to 25% [8, 15] . The pathological characteristics of HCC include its multistep progression from a low-grade (LGDN) to a high-grade dysplastic nodule (HGDN) to early HCC, ultimately developing into overt HCC ('progressed' type) [16, 17] .
LGDNs do not show absolute potential malignancy while HGDNs must be considered as true premalignant lesions, showing progression into definite malignancy during a variable time range [18] .
Early Detection and Accurate Definition of Nodules
Consequently, the early detection and accurate definition of nodules as preneoplastic lesions or early HCC is of paramount importance since it has critical implications; dysplastic lesions should be followed by regular imaging studies since at least one third of them develop a malignant phenotype and, conversely, early tumors should be treated with potentially curative procedures, such as resection, transplantation and percutaneous ablation [8] . Therefore, it is crucial to provide reliable tools for a final diagnosis before the 2-cm cutoff is reached. Delaying the diagnosis until after the 2-cm cutoff leads to increased levels of treatment failure or tumor recurrence since satellites and microscopic vascular invasion rise exponentially beyond this cutoff size [8] .
Up to the year 2000, diagnosis was based on biopsy which, however, has limitations either due to feasibility (owing to location, risk of complications or needle track seeding), or related to accuracy in differentiating HGDNs and early HCCs since stromal invasion (the presence of the infiltration of cancer cells in the portal area), the pathological hallmark of HCC, can be difficult to identify in biopsy specimens even for an experienced pathologist [8] . In 2005, the EASL panel of experts and the AASLD guidelines declared that HCC radiological hallmarks are contrast uptake (washin) in the arterial phase and washout in the venous/late phase [19] . The presence of fat or a lateenhancing pseudocapsule ('corona enhancement') are complementary features, such as a mild-moderate hyperintensity on T2-weighted MRI images and restricted diffusion on diffusion-weighted imaging sequences. A noninvasive diagnosis is established according to the flow chart shown in figure 1 .
However, even using MRI and multidetector computed tomography (MDCT) state-of-the-art technology and following the diagnostic hallmarks of HCC as defined by the EASL-AASLD guidelines, several studies assessing pathological correlations have shown a false-negative rate of 25-30% for detecting tumors <2 cm [20] [21] [22] . This underestimation is explained by the peculiar modifications of the vascular supply to premalignant lesions and early HCCs, which are mainly fed by a portal venous flow, in contrast to overt 'progressed' HCCs, which are mainly supplied by an arterial flow. During hepatocarcinogenesis, portal flow decreases progressively and nodule arterialization increases due to the development of unpaired arteries (capillarization). Arterial tumor vessels develop with increasing tumor diameter [23] [24] [25] [26] . Inasmuch as many early HCCs and almost all HGDNs do not show the typical vascular HCC pattern on dynamic MDCT or MRI, they are difficult to detect by their vascular behavior, frequently being 'atypical' in displaying either a hypervascular pattern in the arterial phase without portal washout or being hypovascular in both the arterial and the portal phases.
The reported incidence of atypical/hypovascular nodules in dynamic studies varies according to diameter, with nodules ranging more frequent from <1 to 1.5 cm ( table 1 ) [22, [27] [28] [29] [30] . In a series of 127 cirrhotic patients under ultrasound (US) surveillance with nodules in the size range of ≤ 2 cm, the incidence of atypical/hypovascular lesions was high (29%), and approximately one third of these were HGDNs or early HCCs (32%) [28] . In a more recent series of 4,474 solitary histologically proven HCCs <3 cm, atypical/hypovascular HCC accounted for 18% and was confirmed to be biologically less aggressive owing to the higher incidence of a well-differentiated grade, smaller tumor size, and the lower incidence of microvascular invasion and micrometastases [30] . Other authors have reported a prevalence of 28.3% of nodules with atypical enhancement among 304 pathologically confirmed HCCs; compared with HCCs having typical enhancement, these tumors had a significantly smaller tumor size, lower histologic grade, a worse Child-Pugh class and significantly lower serum tumor marker levels (α-fetoprotein and protein induced by vitamin K absence/antagonist-II), which are also known as strong prognostic markers for HCC [31] .
Diagnostic Imaging Modalities
In this perspective, the introduction of a new MRI contrast agent capable of diagnosing malignant precursors of HCC based not only on vascular behavior but also on hepatocellular function, can be considered revolutionary [32, 33] . Currently available contrast agents of this type include gadoxetic acid (gadolinium-ethoxybenzyl-dieth- and gadobenate dimeglumine (gadolinium benzyloxypropionictetra-acetate, Gd-BOPTA; MultiHance ® , Bracco, SpA, Milan, Italy). These paramagnetic gadoliniumbased contrast media combine the properties of a conventional extracellular agent, thus enabling dynamic perfusion imaging, and a hepatobiliary (HB) agent, allowing the evaluation of delayed hepatocyte uptake with strong liver enhancement followed by biliary excretion. Both agents provide comparable maximum enhancement of the liver parenchyma [34] . The main differences between these two agents are the degree and the timing of the hepatocyte uptake; with Gd-BOPTA, only 2-4% is taken up by functioning hepatocytes and subsequently excreted with the bile (as compared to 50% using Gd-EOB-DTPA) and the acquisition time of the HB phase (HBP), where hepatocytes reach maximum signal intensity, occurs later than that of Gd-EOB-DTPA (60-120 vs. 20 min after contrast administration). Therefore, these disparities have resulted in Gd-EOB-DTPA becoming the most used HB agent in clinical practice since it became commercially available in Europe in 2004 and in Japan in 2008. Gd-EOB-DTPA enters the hepatocytes through the organic anion transporting the polypeptides OATP1B1 and OATP1B3 located at the sinusoidal membranes, and is excreted into the bile via multidrug resistance protein 2 (MRP2) located at the bile-canalicular membranes of hepatocytes [35, 36] . During the HBP, the majority of HCCs appear hypointense due to the underexpression of OATP1B1/B3, thus reducing Gd-EOB-DTPA hepatocyte intake. When OATP1B1/B3 expression is maintained, HCC intensity depends on the expression of MRP2. In the majority of HCCs, MRP2 is overexpressed, thus increasing the Gd-EOB-DTPA hepatocyte output responsible for HCC hypointensity. Changes in the expression of these transporters occur at an early stage of hepatocarcinogenesis [37] , and the uptake reduction of Gd-EOB-DTPA precedes vascular changes, such as the decline in the portal blood flow [38, 39] . Regenerative nodules, or LGDNs, are expected to exhibit normal expression of the uptake transporter OATP1 and the excretory transporter MRP2; they take up contrast material and appear enhanced as does the surrounding liver, whereas a variable proportion of HGDNs will begin to show a lack of uptake of gadoxetic acid, resulting in overlap with early HCCs.
A minority (5-10%) of HCCs are iso-or hyperintense relative to the liver in the HBP. This can be due to the accumulation of Gd-EOB-DTPA in the cytoplasm of tumor cells, due to decreased MRP2 expression or due to its excretion by hepatocytes with normal MRP2 expression, but trapped in the lumina of the pseudoglands unconnected to normal bile ducts [40] .
Since Gd-EOB-DTPA has become available commercially, many articles focusing on EOB-MRI-based HCC diagnosis have been published. A PubMed search in May 2014 using 'Gd-EOB-DTPA liver MRI' as key words identified 568 studies, 378 [66.5%] coming from Asiatic investigators, especially from Japan and South Korea, 155 (27.5%) published by European groups and the rest (6%) from North American researchers.
European Literature
The European literature mainly investigated the additional value of EOB-MRI in the detection and characterization of cirrhotic nodules in comparison with dynamic MRI and/or MDCT. Marin et al. [41] demonstrated that EOB-MRI with the combined interpretation of dynamic triple-phase MRI and HBP-MRI significantly improved the sensitivity of HCC detection (72%) compared with either dynamic MRI (63%) or MDCT images alone (61%; p = 0.008 and 0.001, respectively). This result was even more valuable for lesions 1-2 cm in diameter. Haradome et al. [42] have demonstrated a significant improvement in the diagnostic performance of dynamic MRI by adding the HBP evaluation of EOB-MRI ('combined MRI'), particularly in small isointense lesions during the portal or equilibrium phases. The addition of the HBP increased the sensitivities for all lesions from 75.0 to 86.7 and from 78.3 to 86.7% for two readers, respectively, and significant differences were achieved in sensitivity between combined MRI and MDCT (p = 0.0045 for reader 1 and p = 0.0126 for reader 2), especially for early HCCs <1.5 cm. Our group additionally confirmed that in lesions <2 cm, the addition of HBP to dynamic MRI improved sensitivity up to 99.4%, with a net gain of 11% in sensitivity and of 32.5% in the negative predictive value for HGDN/early HCC detection [28] . In another study, we tested 111 atypical cirrhotic nodules to determine the best marker of malignancy either alone or in combination among hypointensity on the HBP, arterial, portal-venous and equilibrium-phase behavior on dynamic EOB-MRI and T2-weighted MRI hyperintensity. We found that HBP hypointensity by itself was the strongest marker of malignancy, with 88% sensitivity, 91% negative predictive value and 93% diagnostic accuracy, significantly su- perior to any other feature alone or in combination in identifying high-risk nodules (HGDNs/early HCC/ overt HCC; fig. 2 ). The malignancy detection rate reached 100% when associated with arterial hypervascularity [43] . In another study carried out in our institution, we evaluated the contribution of HBP-EOB-MRI in clinical practice in diagnosing small HCCs in cirrhotic patients under US surveillance who had all also been studied with contrast-enhanced US, MDCT and dynamic MRI. All HCCs displayed hypointensity in HBP-EOB-MRI. Seven nodules were discovered only due to HBP hypointensity at EOB-MRI associated with washout in the portal/venous phase not preceded by arterial hyperenhancement; these could have been missed using any of the other imaging techniques since they lacked the typical vascular pattern. Double hypointensity in the portal/venous phase and HBP without hyperenhancement in the arterial phase could be suggested as a new MRI pattern, with a 100% positive predictive value for hypovascular HCC ( fig. 3 ) [44] . In a series of 102 nodules, Bartolozzi et al. [45] further confirmed that HBP hypointensity has a positive predictive value of 100%, indicating nodule premalignancy/malignancy independently of vascular enhancement. All hypovascular HCCs were HBP hypointense as were the majority (70%) of HGDNs. Since HGDNs may be considered premalignant lesions, HBP hypointensity is a highly specific tool for the detection of both malignant and premalignant nodules, indicating the need for close surveillance in the latter.
Asian Literature
The Asian literature provided the most important contribution to the imaging-pathological correlation of both HBP-hypointense and -hyperintense nodules at EOB-MRI and on their fate during the follow-up. The Asian researchers first proved that EOB-MRI is the most useful imaging technique for differentiating small HCCs, including early HCCs, from benign nodules, demonstrating that the HBP signal intensity of EOB-MRI decreases during multistep hepatocarcinogenesis [46] . Nodule hypointensity in HBP is common in early HCC and is almost always absent in HGDNs as well as in LGDNs [37, 47] . 
East-West Differences
The main difference between the European and the Asian experiences, especially the Japanese ones, is the discrepancy in the histologic attribution of hypointense nodules in HBP, mainly diagnosed as HGDNs by Western pathologists and as early HCCs by Eastern pathologists. The pathological features of early HCC are very similar to those of HGDNs, and these two entities can only be differentiated by the presence of stromal invasion in early HCC, as stated in 2009 by the International Consensus Group for Hepatocellular Neoplasia [48] . By using the new ICGHN criteria also in the European case studies, probably, what was diagnosed as an HGDN actually corresponds to an early HCC.
In a variable time range, hypovascular HBP-hypointense nodules may acquire the typical hypervascular pattern of HCC, indicating evolution into progressed HCC, and they should therefore be considered high-risk lesions, especially when they surpass 1.5 cm [30, [49] [50] [51] [52] . The reported risk of arterialization of HBP-hypointense nodules is 37.6% when measuring >1 cm with a 1-year cumulative risk of 15.6% [49] , 16.9% for nodules measuring <1.5 cm and 77.3% for nodules ≥ 1.5 cm [50] . Kim et al. [51] and Hyodo et al. [52] reported a 1-year cumulative risk of 31-35%, including nodules <0.5 cm. The MRI features considered to be predictors of progression to hypervascular HCC are: (a) hyperintensity on high-b-value diffusion-weighted images ( b = 800 s/mm 2 ) [51] ; (b) hyperintensity on T1-weighted images and fatty degeneration [53] , and (c) the combination of T2-weighted image hyperintensity and tumor volume doubling time <542 days [49] [50] [51] [52] .
The clinical impact of adding EOB-MRI to triplephase MDCT on therapeutic decisions in early-stage HCC was evaluated by Yoo et al. [54] . After adding EOB-MRI, 33.3% of decisions were changed from the previous choice based on MDCT alone; thus, performing EOB-MRI before deciding on curative treatment for early-stage HCC may improve the accuracy of the therapeutic strategy.
In a minority of cases, early HCC may appear as HBP iso-hyperintense, similar to large regenerative nodules, thereby making early HCC as a kind of 'wolf in sheep's clothing' [37] . However, it has been demonstrated that iso-to hyperintense HCC on HBP is a particular form of HCC with biologically less aggressive features, significantly higher differentiation grades, less frequent portal vein invasion and a longer time to recurrence after surgery than hypointense HCCs. Therefore, the signal intensity of HCCs on HBP-EOB-MRI is a useful imaging biomarker and suggests the genetic background of HCCs [31, 46] . Unfortunately, the Western guidelines have not advanced in the same way as the above-mentioned European literature [41] [42] [43] [44] [45] ; neither the AASLD [7, 55] nor EASL-EORTC guidelines [6, 8] have included EOB-MRI in the diagnostic flowchart and in the follow-up, and they also do not acknowledge the diagnostic superiority of dynamic MRI over MDCT, which has been widely demonstrated [41, 42] . On the other hand, the Italian Association for the Study of the Liver recommendations [56] recognizes these topics and introduces some statements, such as 'multiphasic MRI with hepatocyte-specific contrast medium may provide additional clues to the diagnosis of HCC and is superior to CT for intrahepatic staging of the tumor' and 'intrahepatic staging of HCC should be assessed by MRI whenever the patient appears to be a potential candidate for surgical or ablative treatment, as this radiological technique is more accurate than CT'.
Thus, the Western approach is considerably different from the Japanese guidelines proposed in 2010 in which EOB-MRI was included in the diagnostic flowchart for the first time [23] and which have recently been updated [57] , stating that the first-line diagnostic technique of a lesion detected during US surveillance should be dynamic EOB-MRI, with MDCT limited to cases in which MRI is not available. There are several underlying reasons for not including EOB-MRI in the EASL-AASLD diagnostic strategies. HBP-hypointense nodules, which are considered premalignant/malignant and therefore subject to CT-or US-guided biopsy or ablative treatment when >1 cm, remain undetected at basal US, at contrast-enhanced US or at MDCT. The absence of a US contrast agent, such as Sonazoid (Daiichi-Sankyo, GE Tokyo, Japan) in the Western world does not allow identification and the consequent treatment of HBP-hypointense nodules as recommended by the EASL-AASLD guidelines. Moreover, no surgical option is feasible for these nodules, since, according to EASL-AASLD guidelines, a definitive diagnosis of HCC is not achieved inasmuch as the typical vascular hallmarks, which could indicate the surgical approach, are absent. Therefore, in Western countries, HBP-hypointense nodules >1 cm are 'limbo' lesions, and a definite policy is still lacking, even when EOB-MRI is routinely used.
The correct follow-up timing for HBP-hypointense nodules is not easy to establish; a prospective study assessing the reliability and cost-effectiveness of a close follow-up (at least 6 months) could be proposed, regardless of nodule size. Until then, some clinical scenarios can be identified in which a relatively short follow-up period would be desirable:
(1) EOB-MRI follow-up at least every 6 months in patients with HBP-hypointense nodules ≥ 1 cm;
(2) EOB-MRI follow-up at least every 6 months in super-high-risk patients (hepatitis B-and C-related cirrhosis) with HBP-hypointense nodules of any size [23, 57] ; (3) EOB-MRI follow-up at least every 6 months in patients on the waiting list for liver transplantation who underwent a downstaging protocol, with HBP-hypointense nodules of any size.
Conclusion
EOB-MRI has opened new horizons in the early diagnosis of HCC and in differentiating premalignant from malignant lesions due to the fact that alterations in membrane transporters during hepatocarcinogenesis occur earlier than vascular changes. Unlike the Japanese guidelines, the EASL-AASLD guidelines still do not take into account this contrast agent, possibly due to the difficulty in the management of HBP-hypointense nodules >1 cm, which are mostly undetectable at US/contrast-enhanced US, in the absence of Sonazoid on the market. Since, in Western radiological practice, EOB-MRI is routinely used, a revision of the Western guidelines is advisable, at least for setting the proper timing of follow-up for the 'limbo' nodules, which show atypical vascular behavior but are detected as hypointense on HBP-EOB-MRI, so as to promptly identify the onset of nodule arterialization.
